Alergo Med Osrodek Badan Klinicznych Sp. z o.o.
- Address
- lock Available on a paid plan
Alergo Med Clinical Research Center
Alergo Med Osrodek Badan Klinicznych is a specialized clinical research facility focusing on respiratory and allergic diseases. The center conducts advanced Phase III and Phase IV clinical trials investigating novel therapeutic approaches and biosimilar products for patients with complex respiratory and immunological conditions.
- Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis treatment optimization
- Severe asthma management with triple combination therapies
- Chronic spontaneous urticaria and biosimilar therapeutic equivalence studies
- Seasonal allergic rhinitis and rhinoconjunctivitis immunotherapy in pediatric populations
The research center demonstrates particular expertise in triple therapy regimens for respiratory diseases, including combinations of inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), and long-acting muscarinic antagonists (LAMA). Their clinical portfolio spans both adult and pediatric populations, with emphasis on inadequately controlled disease requiring advanced therapeutic interventions. The facility's research activities encompass acute exacerbation prevention, long-term efficacy evaluation, and comprehensive safety monitoring across diverse allergic and respiratory conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 37 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1Celldex Therapeutics Inc.2active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Celldex Therapeutics Inc.3trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Alergo Med Osrodek Badan Klinicznych Sp. z o.o.
lock Showing 1 of 28 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Barzolvolimab in Participants with Cold-Induced Urticaria and Symptomatic Dermographism | Celldex Therapeutics Inc. | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 37 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Glycopyrronium Bromide | 4 | Unknown | 2021-04-29 | 2026-07-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.